Oral Topical Formulation, ARMS-I, Provides Protection Against Upper Respiratory Infections as well as Reducing Severity and Duration of Cold

CLEVELAND, Feb. 7, 2017 /PRNewswire/ -- The findings of a randomized proof-of-concept clinical trial demonstrating that the oral spray formulation, ARMS-I, provided protection against upper respiratory tract infections ("URIs") in the enrolled study participants, while reducing the severity and duration of cough and sore throat have just been released.

Funded by ARMS Pharmaceutical, the double-blinded, placebo-controlled trial was conducted by University Hospital's Cleveland Medical Center's Division of Infectious Diseases and Case Western Reserve University. The conclusion of the study states, "ARMS-I is safe and well-tolerated, and it reduces influenza symptoms. This product has the potential to prevent viral upper respiratory tract infections."

Chief Scientific Officer of ARMS Pharmaceutical, Dr. Mahmoud Ghannoum said, "The results confirm that our ARMS-I technology has tremendous potential to lead the next generation of drugs in not only the prevention of many upper respiratory infectious diseases, such as influenza, rhinovirus and respiratory syncytial virus, but in the treatment of them as well." 

ARMS-I is a patented formulation, comprising a broad-spectrum antimicrobial agent (cetylpyridinium chloride, "CPC") and components (glycerin and xanthan gum) that form a barrier on the host mucosa, thus preventing viral contact with the host cells and invasion. 

The U.S. Food and Drug Administration ("FDA") has accepted the company's Investigational New Drug Application ("IND") for a pharmacokinetic trial of its ARMS-I drug, as the company continues to study and develop the use of ARMS-I for its first indication as a potential drug for the prevention of influenza.

"It is an exciting time for the company as we actively begin discussions with potential strategic partners to bring ARMS-I to market, a drug with the potential to help millions of people prevent influenza without the worries of side effects or viral resistance," added Afif Ghannoum, Chief Executive Officer of ARMS Pharmaceutical.

About ARMS Pharmaceutical LLC
ARMS Pharmaceutical LLC, a clinical stage pharmaceutical company, was founded in 2013. The company focuses on the R&D of its ARMS technology platform. ARMS-I is the company's lead drug candidate for the prevention of influenza. Through strategic partnerships, ARMS Pharmaceutical plans to commercialize its ARMS platform for the prevention and treatment of various infectious diseases.

Media Contact:
BLAZE PR / Matt Kovacs
[email protected]
310-395-5050

SOURCE ARMS Pharmaceutical LLC

Related Links

https://www.bioohio.com/item/arms-pharmaceutical-llc